Literature DB >> 23323552

Perspectives on clinical translation of smart nanotherapeutics.

Joyce Lee, Kit S Lam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23323552      PMCID： PMC4560357          DOI： 10.4155/tde.12.112

Source DB:  PubMed          Journal:  Ther Deliv        ISSN： 2041-5990


× No keyword cloud information.
  25 in total

Review 1.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.

Authors:  H Maeda
Journal:  Adv Enzyme Regul       Date:  2001

2.  A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer.

Authors:  Kai Xiao; Juntao Luo; Wiley L Fowler; Yuanpei Li; Joyce S Lee; Li Xing; R Holland Cheng; Li Wang; Kit S Lam
Journal:  Biomaterials       Date:  2009-08-05       Impact factor: 12.479

3.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Authors:  William J Gradishar; Sergei Tjulandin; Neville Davidson; Heather Shaw; Neil Desai; Paul Bhar; Michael Hawkins; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

4.  Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice.

Authors:  Anatoly N Lukyanov; Zhonggao Gao; Laureen Mazzola; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 5.  Nanotechnology applications in cancer.

Authors:  Shuming Nie; Yun Xing; Gloria J Kim; Jonathan W Simons
Journal:  Annu Rev Biomed Eng       Date:  2007       Impact factor: 9.590

6.  Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies.

Authors:  Cristianne J Rijcken; Cor J Snel; Raymond M Schiffelers; Cornelus F van Nostrum; Wim E Hennink
Journal:  Biomaterials       Date:  2007-10-03       Impact factor: 12.479

7.  In vivo tumor cell targeting with "click" nanoparticles.

Authors:  Geoffrey von Maltzahn; Yin Ren; Ji-Ho Park; Dal-Hee Min; Venkata Ramana Kotamraju; Jayanthi Jayakumar; Valentina Fogal; Michael J Sailor; Erkki Ruoslahti; Sangeeta N Bhatia
Journal:  Bioconjug Chem       Date:  2008-07-09       Impact factor: 4.774

8.  Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo.

Authors:  Shuxian Song; Dan Liu; Jinliang Peng; Hongwei Deng; Yan Guo; Lisa X Xu; Andrew D Miller; Yuhong Xu
Journal:  FASEB J       Date:  2009-01-05       Impact factor: 5.191

9.  A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation.

Authors:  T Hamaguchi; K Kato; H Yasui; C Morizane; M Ikeda; H Ueno; K Muro; Y Yamada; T Okusaka; K Shirao; Y Shimada; H Nakahama; Y Matsumura
Journal:  Br J Cancer       Date:  2007-06-26       Impact factor: 7.640

10.  Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.

Authors:  Y Matsumura; T Hamaguchi; T Ura; K Muro; Y Yamada; Y Shimada; K Shirao; T Okusaka; H Ueno; M Ikeda; N Watanabe
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640
View more
  2 in total

1.  Developing a Nanoparticle-Delivered High-Efficacy Treatment for Infantile Hemangiomas Using a Mouse Hemangioendothelioma Model.

Authors:  Hakan Orbay; Yuanpei Li; Wenwu Xiao; Simon R Cherry; Kit Lam; David E Sahar
Journal:  Plast Reconstr Surg       Date:  2016-08       Impact factor: 4.730

Review 2.  Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers.

Authors:  Yuanpei Li; Kai Xiao; Wei Zhu; Wenbin Deng; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-21       Impact factor: 15.470
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.